CHICAGO, April 6 /PRNewswire-FirstCall/ -- The Female Health Company (OTC:FHCO) (BULLETIN BOARD: FHCO) announced today that Robert Nelson has been appointed Director, Program and Sales. Nelson comes to the newly formed position at FHC with over ten years of sales experience in the pharmaceutical industry. He also worked with Population Services International (PSI) in developing promotional campaigns, public awareness campaigns and education outreach programs in Malawi, Kenya and Zambia as well as training programs for East and Central African countries. Mr. Nelson earned his BA in Business from Westminster College and a Masters in Public Health from SUNY Downstate Medical Center, Brooklyn, New York. Mr. Nelson will be based in FHC's London Office. "Robbie is an outstanding addition to our global team. He brings the experience we need to support procurement of the FC female condom with the education outreach programs needed to support FC introduction and to expand its availability to women in the developing world," said Mike Pope, Vice President and General Manager. "Robbie joins the company with a proven track record in developing sales strategies linked with education and awareness programs. This position broadens the support for FC female condom accessibility working with our many commercial and public agency partners worldwide." About The Female Health Company, Inc. The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC Female Condom(R), which is primarily distributed by public health organizations and donor groups in over 90 developing countries around the world. Worldwide, the Female Condom is available in various programs in 108 countries. The Company owns certain worldwide rights to the FC Female Condom(R), including patents that have been issued in the United States, United Kingdom, Japan, France, Italy, Germany, Spain, the European Patent Convention, the People's Republic of China, Canada, South Korea and Australia. FC Female Condom(R) is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. "Safe Harbor" statement under the Private Securities Litigation Reform Action of 1995: The statements in this release which are not historical fact are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated. For more information about the Female Health Company visit the Company's web site at http://www.femalehealth.com/ and http://www.femalecondom.org/ . If you would like to be added to an e-mail alert list, please send an e- mail to . DATASOURCE: The Female Health Company CONTACT: William R. Gargiulo, Jr., +1-231-526-1244, or Donna Felch, +1-312-595-9123, both of The Female Health Company Web site: http://www.femalehealth.com/ http://www.femalecondom.org/

Copyright